SUMMARY Substantial levels of acyclovir were detected in the aqueous and vitreous of New Zealand rabbits at various time intervals following subconjunctival injection. Intravitreal penetration of acyclovir after topical application was poor.
Acyclovir is an antiviral agent that possesses substantial activity and specificity against most members of the herpes simplex virus family with the possible exception of cytomegalovirus.' Acyclovir shows little toxicity toward uninfected human cells.2 This preliminary study was designed to evaluate the intraocular levels of the drug at different time intervals following subconjunctival injection and topical administration. To the best of our knowledge no other report describes intraocular penetration of acyclovir following subconjunctival administration or vitreous levels after topical application ofacyclovir.
Materials and methods
A total of 47 New Zealand white rabbits, weighing approximately 2 kg each, were divided into three groups for this study.
Part A. The animals were anaesthetised with an intravenous injection of ketamine hydrochloride. A single 25 mg injection of acyclovir sodium (0.5 ml of a 50 mg/ml (50 g/l) solution) was given under the bulbar conjunctiva of one eye of each rabbit. At (Table 5) .
Intraocular acyclovir levels after subconjunctival and topical administration Topical application of acyclovir resulted in vitreous levels well below the therapeutic range for members of the HSV family. Subconjunctival injection with 25 mg of the sodium salt of acyclovir produced, in most instances, aqueous and vitreous levels sufficient to inhibit members of the HSV family with the possible exception of CMV. The vitreous acyclovir levels remained in therapeutic proportions for at least three hours after injection. Therapeutic aqueous levels for HSV I and HSV II were present at 18 hours after injection, but vitreous levels were subtherapeutic for all members of the HSV family except HSV I. The variation in acyclovir levels probably resulted in part from an uneven absorption J Schulman, G A Peyman, R Fiscella, D Greenberg, M B Horton, and P de Miranda due to crystallisation from the subconjunctival injection. This occurred only with the higher dose of acyclovir. The second part of the experiment (subconjunctival injection of 2 5 mg of acyclovir) produced aqueous levels in excess of the MIC for all members of the HSV family except CMV for at least three hours after injection. Negligible levels of acyclovir were detectable 22 hours after injection. Vitreous levels were therapeutic for HSV I, HSV II, VZV, and EBV, but not CMV during the first three hours after injection.
Patients with herpes simplex retinitis have had substantial visual loss and retinal damage.7'" A recent communication'2 has suggested an association between acute retinal necrosis and HSV infection. HSV has been demonstrated in the anterior chamber in iritis, keratouveitis, and disciform corneal oedema with associated iritis.'ll Herpes virus particles also have been detected in an iridectomy specimen removed from a patient with herpetic uveitis, deep keratitis, and secondary glaucoma.'6 Our findings indicate that subconjunctival injection of acyclovir may provide effective drug levels for the primary or adjunctive treatment of deep herpetic disease such as retinitis, keratouveitis, iritis, and possibly acute retinal necrosis. Caution must be exercised, however, in making recommendations based on data obtained only from rabbit eyes. Subconjunctival acyclovir infection should avoid toxic reactions reported after parenteral administration. 
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